Key takeaway: The investor presentation from Krsnaa Diagnostics Limited, dated August 14, 2026, provided an overview of the company's unaudited financial results for the quarter ended June 30, 2026. Krsnaa Diagnostics reported a revenue of INR 2,355 million, reflecting a 22% increase from INR 1,930 million in the same quarter of the previous year. EBITDA was reported at INR 588 million, a 12% increase, while the EBITDA margin decreased to 25%. The company noted a decline in PAT to INR 166 million, down 19% year-over-year. The presentation highlighted Krsnaa's extensive network, including 191 CT/MRI centers and 212 pathology labs, serving over 76 million patients in the last five years. The company emphasized its commitment to affordable healthcare, with retail revenue growth of 64% year-over-year and a focus on expanding its reach and patient trust across India.

Key takeaway: Krsnaa Diagnostics Limited held its Q4 FY '26 earnings conference call on May 26, 2026, to discuss its financial results. Management highlighted the company's mission to enhance public health care through a PPP-led model, providing affordable diagnostics to underserved populations. For FY '26, Krsnaa reported revenues of approximately INR 7,728 million, with a PAT of INR 1,014 million, marking significant growth. The company operates over 190 CT and MRI centers and 147 pathology labs, processing nearly 59 million tests. Management noted a strategic focus on retail expansion, which now contributes about 8% of total revenue. They also discussed ongoing capital investments of nearly INR 5,000 million to support growth and infrastructure development. The management emphasized the long-term potential of their integrated health care platform, despite challenges in project timelines and government collaborations. The call concluded with a commitment to maintaining operational efficiency and improving cash flow management.

Key takeaway: Krsnaa Diagnostics Limited reported its financial results for the quarter and year ended March 31, 2026, highlighting its position as one of India's largest integrated diagnostic service providers. The presentation detailed a 4% increase in revenue to INR 1,926 million for Q4 FY26 compared to INR 1,861 million in Q4 FY25, with a 102% rise in profit after tax (PAT) to INR 417 million. The company served over 4.8 million patients in Q4 FY26, maintaining a strong operational presence across 18 states and 331 districts. Krsnaa emphasized its commitment to affordable diagnostics, offering services at significantly lower prices than competitors. The company also noted its expansion plans, including the addition of more CT/MRI centers and collection points, and highlighted its achievements in accreditation and quality standards. The document included a disclaimer regarding forward-looking statements and the inherent risks associated with them.

Key takeaway: Krsnaa Diagnostics Limited held its Q3 FY '26 earnings conference call on February 6, 2026, to discuss its financial results for the quarter and nine months ended December 31, 2025. Management emphasized the company's long-term vision of building a resilient healthcare institution rather than focusing on short-term metrics. They reported a revenue of INR 1,812 million for the quarter, reflecting a year-on-year growth of approximately 4%. The company highlighted its unique diagnostics platform, which includes a significant investment in radiology, and noted that it has remained EBITDA and PAT positive since inception. Management also discussed the impact of seasonality on Q3 results and the recovery of INR 130 crores in government receivables, which strengthened cash flow. They mentioned ongoing expansion efforts, including the Rajasthan project, and the launch of the Apulki Healthcare Hospital in Pune. The call concluded with management expressing confidence in their strategy and operational discipline.

Key takeaway: The investor presentation from Krsnaa Diagnostics Limited, dated February 5, 2026, provided an overview of the company's unaudited financial results for the quarter and nine months ended December 31, 2025. Krsnaa Diagnostics reported a 9% increase in revenue for 9M FY26 compared to 9M FY25, reaching INR 5,802 million, with an EBITDA margin of 28%. The presentation highlighted the company's extensive network, including 190 CT/MRI centers and 140 pathology labs across 18 states, serving over 81 million patients since inception. Retail revenue showed significant growth, increasing by approximately 8 times year-over-year. The company also announced the launch of its first Apulki Healthcare Hospital, aimed at providing cancer and cardiac care under a public-private partnership model. Management emphasized their commitment to affordable diagnostic services, with prices significantly lower than competitors.